Endoscopic methods are increasingly used in the diagnosis of cystic lesions of the pancreas. The two major endoscopic approaches are endoscopic ultrasonography (EUS) and transpapillary diagnosis. EUS-guided fine-needle aspiration cytology and EUS-guided fine needle-based confocal laser endomicroscopy have been used in the differential diagnosis of mucinous and non-mucinous pancreatic cysts. EUS is the most sensitive modality for detecting mural nodules (MN) in intraductal papillary mucinous neoplasms (IPMN). Contrastenhanced harmonic EUS (CH-EUS), as an add-on to EUS, is useful for identifying and characterizing MN. Recent studies show that CH-EUS has a sensitivity of 60-100% and a specificity of 75-92.9% for diagnosing malignant cysts. Intraductal ultrasonography and peroral pancreatoscopy are especially useful for detecting MN and IPMN. A recent meta-analysis showed that cytological assessment of pancreatic juice using a transpapillary approach had a pooled sensitivity, specificity, and accuracy of 35.1%, 97.2%, and 92.9%, respectively, for diagnosing malignant IPMN. Further studies are warranted to determine the indications for each of these novel techniques in assessing cystic lesions of the pancreas.
INTRODUCTION

P ANCREATIC CYSTIC LESIONS include intraductal papillary mucinous neoplasms (IPMN), serous neoplasms (SN), mucinous cystic neoplasms (MCN)
, and pseudocysts. Typically, IPMN are multilocular and located in the pancreatic head, whereas most MCN are round in shape and located in the pancreatic tail. Mural nodules (MN), visualized as the projections of epithelial cells, are often detected in mucinous cysts, such as MCN and IPMN, but not in SN. MCN and IPMN have malignant potential; however, these lesions can be followed up without surgery depending on symptoms or the presence of high-risk features. In contrast, SN are generally not considered to have malignant potential. Therefore, the determination of whether these lesions are benign or malignant, as well as their differential diagnosis, is important in determining treatment decisions, such as observation or surgical resection.
Diagnostic approaches include endoscopic ultrasonography (EUS), EUS-guided fine-needle aspiration (EUS-FNA), EUS-guided fine-needle-based confocal laser endomicroscopy (nCLE), and contrast-enhanced harmonic
EUS (CH-EUS).
Other advanced diagnostic techniques include transpapillary approaches, including assessment of pancreatic juice, intraductal ultrasonography (IDUS), and peroral pancreatoscopy (POPS). This review focuses on the endoscopic diagnosis of cystic lesions of the pancreas.
METHODS
M
EDLINE/PUBMED AND THE Cochrane Library electronic database were searched for studies published between January 1995 and February 2018 using the keywords "pancreatic cyst" and "endoscopic". The initial search identified 2536 articles. Of these, 633 articles were deemed relevant to this review based on the screening of their titles. After the evaluation of abstracts, complete texts were obtained for potentially relevant articles. A manual recursive search of the reference sections of these articles was carried out to identify other potentially relevant articles. These articles were reviewed in detail. After a thorough review and adding recent important articles, 77 articles focusing on endoscopic diagnosis of cystic lesions of the pancreas were included. pseudocysts, and is especially useful for detecting small lesions, making a differential diagnosis, and tumor staging.
Endoscopic ultrasonography morphology
Utility for differential diagnosis of pancreatic cystic lesions. A study of 29 patients with pseudocysts found that EUS was much better than computed tomography (CT) for detecting lesions, especially those <2 cm in size (83% vs. 33%). 1 In contrast, EUS has been used in the differential diagnosis of cystic lesions of the pancreas. [2] [3] [4] [5] [6] Main pancreatic duct (MPD) communication is important in differentiating IPMN from SN and MCN. EUS is equivalent to magnetic resonance imaging (MRI) in detecting MPD communication in pancreatic cysts. 2 For example, EUS evaluation of 76 patients with cystic tumors of the pancreas found that eight of 11 monocular cystic tumors were nonneoplastic cysts, 11 of 13 SN had microcystic areas, and MN was present in 25% of MCN and in 38% of IPMN. 4 These findings indicate that EUS is a good modality for assessing the internal structures of pancreatic cystic lesions. [2] [3] [4] [5] [6] However, the diagnostic accuracy of EUS for distinguishing neoplastic from non-neoplastic cysts among eight endosonographers was found to vary from 40% to 93%, suggesting that the level of endosonographer experience could affect patient diagnosis. 7 Utility of differential diagnosis of benign and malignant intrapapillary mucinous neoplasms. International consensus guidelines (2017) regard MN as high-risk stigmata (HRS), 8 with EUS recommended for the evaluation of IPMN with worrisome features (WF). Kamata et al. 5 used EUS for the initial diagnosis of IPMN regardless of the presence or absence of HRS or WF on CT or MRI. That study found that the rate of detection of MN in malignant IPMN was 100% by EUS. In contrast, detection rates by US, CT, and MRI were 47%, 53%, and 53%, respectively. Previous reports also reported that EUS is the most sensitive modality for detecting MN in IPMN. 5, 6, 9 For example, a study evaluating whether EUS-determined MN height could differentiate between benign and malignant IPMN found that a cut-off value of 5.4 mm had a diagnostic accuracy for malignant IPMN of 76.4%. 6 Similarly, a MN >5 mm in height was reported to be an independent factor for malignancy. 10 In contrast, a study assessing MN in 36 patients with IPMN found that the diameters (4.3 vs. 16.4 mm) and widths (5.7 vs. 23.2 mm) of papillary protrusions differed between low-risk and high-risk IPMN. 11 Measurement of MN by US or EUS reported that the odds ratio for malignancy of MN >10 mm was 198 (P < 0.0001). 12 Because the cut-off values for distinguishing between benign and malignant IPMN differed among studies, future large prospective studies are warranted.
Endoscopic ultrasound-guided fine-needle aspiration
Endoscopic ultrasound-FNA of cystic fluid from pancreatic cysts has been carried out to differentiate between malignant and benign lesions and between mucinous and nonmucinous cysts. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] EUS-FNA has been recommended for pancreatic cysts >15 mm in size. 13 Adverse events of EUS-FNA included bleeding in 0.2-6% of patients and infections in 0.2-5%. [14] [15] [16] The risks of these EUS-FNArelated adverse events may be reduced by giving prophylactic antibiotics and/or discontinuation of anticoagulants. However, discontinuation of anticoagulant drugs can increase the risk of cardiovascular events in patients.
Utility of differential diagnosis of benign and malignant pancreatic cystic lesions. A meta-analysis of 18 studies evaluating the utility of EUS-FNA for the diagnosis of pancreatic cystic lesions found that the pooled sensitivity and specificity of cytology for diagnosing malignant pancreatic cysts were 51% (95% CI, 45-58%) and 94% (95% CI, 92-96%), respectively. 17 Classification of suspicious and potential malignancies as outright malignancies did not improve the diagnostic sensitivity of this method. Thus, the sensitivity of cytology using cyst fluid obtained by EUS-FNA was not satisfactory. Sensitivity may be improved using the diagnostic categories of pancreaticobiliary terminology based on the classification scheme of the Papanicolaou Society of Cytopathology. 18 That study classified the results of EUS-FNA into seven categories: Panc 1 (nondiagnostic); Panc 2 (negative for malignancy/neoplasia); Panc 3 (atypical); Panc 4B (neoplastic, benign); Panc 4O (neoplastic, other); Panc 5 (suspicious of malignancy); and Panc 6 (positive/malignant). Use of this scheme in evaluating 41 cystic lesions of the pancreas found that its sensitivity and specificity for diagnosing malignancy or neoplasia with malignant potential were 91.7% and 100%, respectively.
An evaluation of carcinoembryonic antigen (CEA) concentration in cystic fluid of 62 patients with pancreatic cystic lesions showed that the mean CEA concentration was higher in surgically treated patients (7760 ng/mL) than in those with stable lesions (184.7 ng/mL) or increasing cyst size (361.1 ng/mL). 19 Thus, measurements of CEA in cystic fluid analysis can be used to determine optimal follow-up intervals and decide whether surgical resection of pancreatic cystic lesions is required.
Utility of differential diagnosis of mucinous and nonmucinous pancreatic cystic lesions. Differential diagnosis of mucinous and non-mucinous pancreatic cysts includes assessments of viscosity, which has a diagnostic accuracy ranging from 54% to 97%. 22 Measurements of CEA or carbohydrate antigen concentrations in cystic fluid have been reported useful diagnostically (Table 1) . [23] [24] [25] [26] [27] [28] [29] [30] A CEA concentration >800 ng/mL in cystic fluid had a specificity of 98% in diagnosing mucinous cysts of the pancreas. 23 By comparison, another study, using a CEA concentration of 192 ng/mL as a cut-off, found that the diagnostic accuracy for mucinous cysts was 79%, significantly higher than the accuracy of EUS morphology. 24 Concentration of amylase in cystic fluid may also be useful in the differential diagnosis of pancreatic cystic lesions. 23 Amylase concentrations have been reported to be higher in IPMN and pseudocysts than in other pancreatic cysts, with an amylase concentration <250 U/L being indicative of pancreatic cysts except for pseudocysts. 23 In summary, EUS-FNA is useful for the differential diagnosis of mucinous and non-mucinous cysts and benign and malignant cysts. However, the low diagnostic yield, especially for the differential diagnosis of benign and malignant cysts, is a major concern. Moreover, the algorithm of EUS-FNA for the management of pancreatic cystic lesions is unclear. 33 Approaches permitting the evaluation of cyst fluid obtained by EUS-FNA for the early diagnosis or prediction of prognosis are expected in the near future.
Cyst fluid molecular analysis
Genetic changes in cystic fluid cells are also diagnostic of pancreatic cystic lesions. 34 KRAS mutation analysis improved the diagnostic accuracy for malignant IPMN from 66% to 81%, whereas GNAS assays did not. 20 Combination of KRAS mutation analysis and CEA concentration measurements improved the diagnostic sensitivity of the latter alone from 67% to 84% for mucinous cysts. 35 A recent systematic review of 12 articles showed that the combination of cytology and KRAS analysis was useful diagnostically (sensitivity, 71%; specificity, 88%), although KRAS mutational analysis alone had a poor diagnostic ability (sensitivity, 39%; specificity, 95%). 36 Singhi et al. 37 evaluated 626 pancreatic cyst fluids obtained by EUS-FNA using next-generation sequencing and showed that the combination of KRAS/GNAS mutations and TP53/ PIK3CA/PTEN alternation analyses had a sensitivity of 89% and a specificity of 100% for diagnosing advanced neoplasia.
Endoscopic ultrasound-guided fine-needlebased confocal laser endomicroscopy
Endoscopic ultrasound-guided nCLE is a novel technique to evaluate pancreatic cysts by laser-assisted microscopic imaging. [38] [39] [40] This technique enables the evaluation of tissue samples with high resolution (3.5 lm). Utility of differential diagnosis of mucinous and nonmucinous pancreatic cystic lesions. Endoscopic ultrasoundguided nCLE, involving the insertion of a confocal probe through a 19-gauge EUS-FNA needle into the lesion, allows visualization of the microscopic cellular features of pancreatic cystic lesions. EUS-guided nCLE had a sensitivity of 77% and a specificity of 100% in diagnosing mucinous cysts. 39 Moreover, this method had an accuracy of 87% in the diagnosis of SN, which was useful for avoiding unnecessary surgery or follow up. 40 A validation study of EUS-guided nCLE criteria in 49 patients with pancreatic cystic lesions found that the interobserver agreement (j = 0.67) and interobserver reliability (j = 0.78) for diagnosing mucinous cysts were high and that the overall sensitivity, specificity, and accuracy for diagnosing mucinous cysts were 94%, 82%, and 89%, respectively. 41 Thus, EUS-guided nCLE has been carried out to identify IPMN, SN, MCN, and/or pseudocysts, and especially to differentiate mucinous and non-mucinous pancreatic cysts. A limitation of this novel technique is that the diagnostic yield for the differential diagnosis of benign and malignant cysts is unknown. Thus, nCLE cannot replace EUS-FNA for diagnosing pancreatic cystic lesions. Further studies are warranted to clarify the diagnostic yield of nCLE for pancreatic cystic lesions.
Endoscopic ultrasound-through-the-needle biopsy
Recently, several studies reported the utility of EUSthrough-the-needle biopsy (EUS-TTNB) for the diagnosis and risk stratification of the malignancy of pancreatic cystic lesions. [42] [43] [44] [45] [46] This novel technique enables direct sampling from the walls of pancreatic cystic lesions using biopsy microforceps through an EUS-FNA needle. One multicenter study enrolling 56 patients reported that technical success was 100% and the rate of adequate sampling for histological diagnosis was 83.9%. 44 The rate of adverse events was 16.1%, but these were mild and were resolved by conservative therapy. Kovacevic et al. 45 carried out EUS-TTNB in 31 consecutive patients with pancreatic cystic lesions and reported that clinical management was changed in six out of the 31 (19.4%) patients as a result of this evaluation. In some cases, the diagnosis could not be obtained using EUS-TTNB but could be obtained by cytology or cyst fluid evaluation; therefore, it may be important to diagnose using not just one but both of these methods together. 44, 46 Contrast-enhanced harmonic endoscopic ultrasonography Utility of differential diagnosis of benign and malignant pancreatic cystic lesions. Several studies evaluated the utility of CH-EUS for diagnosing pancreatic cystic lesions (Table 2) . [47] [48] [49] [50] [51] [52] [53] [54] [55] Detection by B-mode EUS of MN-like structures in dilated pancreatic ducts of patients with IPMN may result in difficulties determining whether these structures are mucous clots or MN. However, CH-EUS can distinguish these structures by evaluating the presence or the absence of blood flow in the lesion 47, 48 (Figs 1 and  2) . CH-EUS evaluation of MN in 21 patients with IPMN found an avascular pattern in 14 patients, enabling them to avoid unnecessary surgical resection. 48 CH-EUS has been used to classify MN of IPMN into four types. 49 Classification of papillary MN and those suspected of infiltrating the pancreatic parenchyma (types III and IV) as malignant resulted in CH-EUS having a sensitivity, specificity, and accuracy of 60%, 92.9%, and 75.9%, respectively. CH-EUS was used to evaluate 142 patients with BD-IPMN at initial diagnosis and after a median follow up of 42.5 months. 50 Rate of malignant transformation was found to be 6.3%, with multivariate analysis showing that the presence of MN at initial diagnosis and involvement of the MPD were significant predictors of malignant transformation. A comparison of CH-EUS evaluation of MN with pathological findings after surgery in 17 patients who had IPMN with MN found that CH-EUS had a sensitivity of 100% and a specificity of 80% for the detection of MN. 51 Hocke et al. 52 found that contrast enhancement at the cyst wall, septa or MN indicated cystic neoplasia. Similarly, Fusaroli et al. 53 reported that cystic neoplasia was hyperenhanced on CH-EUS. One limitation of CH-EUS is its inability to differentiate between serous and mucinous cysts because their enhancement patterns are similar, 52 ,53 although CH-EUS was able to distinguish between pseudocysts and other pancreatic cysts. 53 CH-EUS assessment of MN height cut-off value has also been analyzed. 47, 54 For example, the optimum cut-off value of MN height was found to be 8.8 mm for diagnosing malignant IPMN, with this height having an accuracy of 93%. 54 By contrast, MN assessment by standard EUS alone had an accuracy of 87%. Evaluation of 70 patients with undetermined pancreatic cysts by standard EUS and CH-EUS showed that their accuracies in diagnosing mucinous cysts by the presence or absence of MN were similar (84% vs. 73%). 47 By contrast, CH-EUS was significantly more accurate than standard EUS in diagnosing malignant cysts (84% vs. 64%). This study also assessed whether CH-EUS and standard EUS measurements of MN height were diagnostic of malignancy, finding that the areas under the receiver operating characteristic curves were 0.93 and 0.84, respectively. The optimal cut-off value of MN height calculated by CH-EUS was 4 mm. Time-intensity curve analysis of MN showed that the nodule/pancreatic parenchyma contrast ratio had a sensitivity and specificity for differentiating between lowgrade and high-grade dysplasia/carcinoma of 93.8% and 92.9%, respectively. 55 Thus, CH-EUS is useful for evaluating MN in pancreatic cysts. Recently, the utility of CH-EUS for surveillance after surgical resection of IPMN was also reported. 56 However, CH-EUS is not necessary in the majority of cases and is not widely used at present. Further studies including the evaluations of indications for CH-EUS are necessary.
Diagnosis by the transpapillary approach
The transpapillary approach is used for detecting lesions, discriminating between benign and malignant or diagnosing tumor extensions, and especially for evaluating IPMN, but Digestive
not SN and MCN, as these lesions generally do not communicate with the pancreatic duct. 57 
Intraductal ultrasonography
Intraductal ultrasonography, which provides high-resolution echoic images of the MPD walls (Fig. 3) , has been reported to be useful for the diagnosis of IPMN. 58 IDUS can determine the heterogeneity of MN and whether invasion of the pancreatic duct walls has occurred. To carry out this technique, the IDUS probe must be directly inserted through the guidewire into the bile duct from Vater's ampulla; therefore, it is technically difficult in cases without MPD dilation.
Utility of differential diagnosis of benign and malignant intrapapillary mucinous neoplasms. Intraductal ultrasonography was found to have a high specificity of 91% in differentiating invasive from noninvasive IPMN, but a low sensitivity of 56%. Combination of IDUS and EUS improved the diagnosis of invasive IPMN. In addition, the combination of IDUS and POPS was useful in differentiating malignant and benign IPMN. 59 Utility of diagnosing tumor extensions of intrapapillary mucinous neoplasms. Intraductal ultrasonography was also useful in diagnosing tumor extensions of IPMN, which was of assistance in determining suitable resection lines. 60, 61 IDUS was especially important for the preoperative evaluation of main-duct (MD)-IPMN. MPD diameter was found to be ≥6 mm in patients with intraductal lateral spread along the MPD from the IPMN. 61 IDUS had a sensitivity, specificity, and accuracy of 92%, 91%, and 92%, respectively, for detecting lateral spread.
Peroral pancreatoscopy
Peroral pancreatoscopy is a good modality for detecting mucosal changes and protrusions in the pancreatic duct, with POPS-guided biopsy enabling histological diagnoses. 62 POPS-guided pancreatic juice cytology had a sensitivity of 62.2% for the diagnosis of IPMN, whereas pancreatic juice collected with a catheter in the absence of POPS guidance had a sensitivity of only 38.2%. 63 Several types of POPS devices have been described (Table 3) . Narrow-band imaging (NBI) can enhance assessments by POPS, as NBI showed better visualization of the surface structure and vascular pattern of tumors than conventional POPS. 64, 65 NBI was also useful in identifying skip lesions of IPMN that were not detectable by conventional POPS. 64 Using ultrathin diameter fiberoptic pancreatoscopy (SpyGlass; Boston Scientific, Marlborough, MA, USA) without a sheath enabled POPS to be carried out using an endoscopic retrograde cholangiopancreatography (ERCP) catheter. 66, 67 Although this technique is highly feasible, cleaning of the pancreatic duct and obtaining biopsy samples are not possible during POPS.
Peroral pancreatoscopy is difficult to carry out in cases without MPD dilation, similar to IDUS. The risks, such as a longer procedure time and ERCP-related complications should be balanced against the expected benefits before POPS is carried out.
Assessment of pancreatic juice by a transpapillary approach
Utility of differential diagnosis of benign and malignant intrapapillary mucinous neoplasms. Assessment of pancreatic juice by a transpapillary approach is useful in the differential diagnosis of benign and malignant IPMN (Table 4) . 10, [68] [69] [70] A meta-analysis of 13 studies that included 483 patients with IPMN found that ERCP cytology had a pooled sensitivity, specificity, and accuracy of 35.1%, 97.2%, and 92.9%, respectively, in the differential diagnosis of benign and malignant IPMN. 68 In this meta-analysis, lavage cytology improved the sensitivity to 45.8%. Lavage cytology has also been shown to be useful in diagnosing bile duct cancer and gallbladder diseases. 71, 72 Balloon catheters have been used for spot shooting of the desired area. 73 In contrast, an evaluation of pancreatic juice cytology obtained by routine preoperative ERCP in 70 patients with IPMN found that the addition of pancreatic juice cytology altered treatment in two patients with branch-duct (BD)-IPMN from observation to surgical resection. 74 Moreover, three IPMNconcomitant pancreatic ductal adenocarcinomas (PDAC) were diagnosed only by ERCP that included pancreatic juice cytology. One potential drawback of ERCP assessment of pancreatic juice cytology, however, is post-ERCP pancreatitis (PEP). 75 Rates of PEP in patients diagnosed with BD-IPMN and MD-IPMN were 17.2% and 3.6%, respectively. 75 Another drawback of cytology by the transpapillary approach is the poor sensitivity of this method, despite its high specificity. New methods, including immunohistochemical (IHC) analysis of markers, are warranted to improve diagnostic accuracy. IHC showed good sensitivity in diagnosing IPMN without MN, but the results may have been affected by selection bias. 76 A report of IHC analysis of pancreatic juice included an evaluation of the cell block method for the diagnosis of malignant IPMN in 138 patients. 70 Using positive staining for p53 or MUC1 and a Ki-67 labeling index ≥10% as indicative of malignancy, the combination of IHC with hematoxylin and eosin (HE) staining had a sensitivity of 79% and a specificity of 100%, whereas HE staining alone had a sensitivity of 50% and a specificity of 100%. A study in 36 patients found that the combination of MUC staining and evaluation of cytological grade was also useful in diagnosing 22 patients with highgrade dysplasia or invasive IPMN, with a sensitivity of 77.2%, a specificity of 85.7%, and an accuracy of 80.5%. 69 In addition, MUC staining of pancreatic juice obtained by ERCP was useful for diagnosing histological subtypes of IPMN. 69, 70 Another study assessed factors associated with malignancy, including tumor, MPD, and MN sizes and CEA concentration in pancreatic juice in 134 patients who underwent ERCP resection of BD-IPMN. 10 That study found that a combination of MN size >5 mm and CEA concentration >30 ng/mL had a positive predictive value for malignancy of 100%. Thus, IPMN may be diagnosed by using a combination of pancreatic juice assessment and other clinical findings.
CONCLUSIONS
T HE TRANSPAPILLARY APPROACH and EUS are useful in evaluating pancreatic cystic lesions, especially IPMN. Endoscopic diagnosis using novel techniques is useful and necessary for assessing pancreatic cystic lesions; however, clear strategies have not yet been developed. 77 Further studies are warranted not only to improve diagnostic ability but also to determine a clear strategy for the use of novel endoscopic techniques for the diagnosis of pancreatic cystic lesions.
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